America of a famous hospital Scientists by Cancer A cell-killing drug has been developed that destroys solid tumors through ‘targeted chemotherapy’.
The pill contains a protein, for example, that acts like a ‘blizzard that can shut down an airline’s main hub and thus stop the flow of only planes carrying cancer cells.’
The protein was developed by a research team at City of Hope Hospital, one of the largest cancer research and treatment organizations in the United States.
A molecule called AOH1996 works by targeting the cancer variant of PCNA, a protein important for DNA replication and tumor growth.
Developed over the past two decades, this drug has proven effective in clinical research to treat breast, prostate, brain, ovarian, cervical, skin and lung cancers.
In this study, published in the medical journal ‘Cell Chemical Biology’, this protein was tested on more than 70 cancer cell lines.
This section contains related reference points (Related Nodes field).
The results showed that the AOH1996 molecule selectively killed cancer cells by disrupting the normal reproductive cycle of the cell. The next step is to advance these findings through clinical trials in humans.
Dr Linda Malkas, PhD, Professor of Molecular Diagnostics and Experimental Therapeutics at City of Hope and MT&BA Professor of Molecular Oncology, Ahmadineja said: ‘PCNA is like a large airline terminal hub with a More air gates are included. The data showed that PCNA is uniquely mutated in cancer cells and this fact helped us develop a drug that would target only the mutated form of PCNA in cancer cells. is.’
He added: ‘Our cancer-killing drug is like a blizzard that shuts down a major airline hub only to stop all flights carrying cancer cells.’
According to him: ‘The results have been promising. AOH1996 can inhibit tumor growth as a monotherapy without inducing toxicity in cell and animal models. The investigational chemotherapy is currently in a phase one human clinical trial at City of Hope.’
The study’s lead author, Long Guo, associate research professor in the Department of Molecular Diagnostics at Beckman Research Institute in the City of Hope, added: ‘No drug has ever targeted PCNA therapeutically. was made because it was considered ‘untreatable’ but clearly City of Hope was able to develop an investigational drug to target a challenging protein.’
According to him: ‘We discovered that PCNA is one of the possible causes of increased nucleic acid replication errors in cancer cells. Now that we know the specific part of the problem and can prevent it, we will go deeper to understand the process to develop more personalized and targeted cancer drugs.’
#Breakthrough #cancer #treatment #tumorkilling #drug #discovered
What are the potential side effects of the new cancer treatment AOH1996 compared to traditional chemotherapy?
**Interview with Dr. Linda Malkas on the New Cancer Treatment Breakthrough**
*Editor:* Today we have the pleasure of speaking with Dr. Linda Malkas, a leading researcher at City of Hope Hospital. Dr. Malkas, your team has recently made headlines with a promising new cancer treatment. Can you tell us about the drug, AOH1996, and how it works?
*Dr. Malkas:* Thank you for having me. AOH1996 is a groundbreaking drug developed over the past two decades. It specifically targets a mutated version of the PCNA protein that plays a crucial role in DNA replication and tumor growth in cancer cells. By leveraging this unique mutation, we can selectively kill cancer cells while sparing healthy ones.
*Editor:* That sounds revolutionary. You mentioned that AOH1996 acts like a ‘blizzard’ disrupting an airline hub. Can you elaborate on that analogy?
*Dr. Malkas:* Certainly! Think of PCNA as a major airline terminal with many gates allowing planes—representing cancer cells—to take off and replicate. AOH1996 can effectively shut down this terminal, halting the flow of cancer cell replication. This targeted approach can lead to more effective treatment with potentially fewer side effects compared to traditional chemotherapy.
*Editor:* You tested this drug on over 70 cancer cell lines. What were the outcomes?
*Dr. Malkas:* The results were promising. We observed that AOH1996 selectively eliminated cancer cells by disrupting their normal reproductive cycle, which is pivotal for tumor growth. We are now preparing for the next stage—clinical trials in humans—to determine the drug’s efficacy and safety.
*Editor:* With applications in multiple cancers like breast, prostate, and lung, do you foresee any challenges in advancing AOH1996 to clinical trials?
*Dr. Malkas:* Every new treatment comes with its challenges, from regulatory hurdles to ensuring it is safe for human use. However, we are optimistic. Our preclinical findings have been encouraging and give us a solid foundation to move forward.
*Editor:* What does this mean for the future of cancer treatment?
*Dr. Malkas:* Innovations like AOH1996 represent a shift towards personalized medicine. If our clinical trials are successful, we could see a new class of targeted therapies that are more effective and have fewer side effects, fundamentally changing how we treat cancer.
*Editor:* Thank you, Dr. Malkas, for sharing these exciting developments. We look forward to hearing more about your progress.
*Dr. Malkas:* Thank you for the opportunity to discuss our work!
